Literature DB >> 22428785

Obinutuzumab (GA101)--a different anti-CD20 antibody with great expectations.

Tim M Illidge.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22428785     DOI： 10.1517/14712598.2012.668881

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN： 1471-2598            Impact factor:   4.388


× No keyword cloud information.
  6 in total

1.  Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity.

Authors:  Sylvia Herter; Martina C Birk; Christian Klein; Christian Gerdes; Pablo Umana; Marina Bacac
Journal:  J Immunol       Date:  2014-01-31       Impact factor: 5.422

Review 2.  Current and future management of follicular lymphoma.

Authors:  Gilles Salles; Hervé Ghesquières
Journal:  Int J Hematol       Date:  2012-10-30       Impact factor: 2.490

3.  Site-specific N-glycan Analysis of Antibody-binding Fc γ Receptors from Primary Human Monocytes.

Authors:  Jacob T Roberts; Kashyap R Patel; Adam W Barb
Journal:  Mol Cell Proteomics       Date:  2019-12-30       Impact factor: 5.911

Review 4.  Targeted drug delivery for cancer therapy: the other side of antibodies.

Authors:  Michael A Firer; Gary Gellerman
Journal:  J Hematol Oncol       Date:  2012-11-09       Impact factor: 17.388

Review 5.  New insights into biology, prognostic factors, and current therapeutic strategies in chronic lymphocytic leukemia.

Authors:  Piotr Smolewski; Magdalena Witkowska; Anna Korycka-Wołowiec
Journal:  ISRN Oncol       Date:  2013-08-22

6.  Retreatment with obinutuzumab: An addition to the therapeutic landscape of chronic lymphocytic leukemia.

Authors:  Sharad Khurana; Salman Ahmed; Victoria R Alegria; Sonikpreet Aulakh; Meghna Ailawadhi; Anshika Singh; Asher Chanan-Khan; Sikander Ailawadhi
Journal:  SAGE Open Med Case Rep       Date:  2019-01-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.